Clinical Trial Update: Phase III PEG-Intron in HIV-infected Patients (Study P00738) [Phase 3]

View source ↗

Summary

This document reports the completion of a Phase III trial (Study P00738) evaluating PEG-Intron in HIV-infected patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• PEG Intron (pegylated interferon alfa-2b)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV Infections, AIDS | Phase 3 | Status: COMPLETED